| Human Genome Sciences: Tests Raise Questions About New Lupus Drug Ketan Desai submits:On Tuesday, April 20, Human Genome Sciences (HGSI) released longer term data from its Bliss 76 Phase III study in Lupus, leading to a stock drop. First, some background.Complete Story » seekingalpha.com |
Families Hear Gene Secrets Children's Hospital Boston has designed a new genetic research project so information gleaned from DNA can benefit not only science, but potentially participants themselves. online.wsj.com |
Study Shows Hope for Gene Therapy Researchers have launched a new gene-therapy trial for children with a rare disease known as "bubble boy syndrome," reflecting fresh hopes that the strategy of delivering working genes can be used to treat many intractable ailments. online.wsj.com |
JOHNSON'S® Brand Launches JOHNSON'S® NATURAL™ Product Line for Babies and Kids - Video SKILLMAN, N.J., Aug. 26 /PRNewswire/ -- JOHNSON'S® Brand, the leading expert in baby skincare, introduces JOHNSON'S® NATURAL™, a line of products that naturally and gently care for baby's skin and hair featuring at least 98 percent plant and fruit-derived natural ingredients. The new line supports the needs of a growing number of moms looking for natural products as part of a natural lifestyle. To view the multimedia assets associated with this release, please click: http://multivu.prnewswire.com/mnr/johnsons/45901/ JOHNSON'S® NATURAL™ product line is formulated with a unique combina feedproxy.google.com |
Avanir Pharma's Pending FDA Approval: The Upside Potential Rockford Coscia submits: I've been looking rather deeply into Avanir Pharmaceuticals (AVNR) and I have to say I’m impressed. There doesn’t appear to be any red flags I can find apart from some recent insider sales and a recent shelf registration (I’ll come back to this in the next Avanir post). Avanir received an 'approvable letter', now known as a complete response letter (CRL), in 2006 for AVP-923 (formerly known as Zenvia). As AVP-923 faces a new PDUFA decision date of October 30, I wanted to take a look at Avanir and evaluate the progress it has made in terms of safety and efficacy since receipt of the initial FDA response. Complete Story » seekingalpha.com |